Literature DB >> 28096163

Large-Scale Evaluation of In Vitro Amphotericin B, Triazole, and Echinocandin Activity against Coccidioides Species from U.S. Institutions.

George R Thompson1,2, Bridget M Barker3, Nathan P Wiederhold4.   

Abstract

Large-scale testing of Coccidioides isolates has not been performed, and the frequency of clinical isolates with elevated amphotericin B or triazole MICs has not been evaluated. Coccidioides isolates (n = 581) underwent antifungal susceptibility testing. Elevated MIC values were observed for fluconazole (≥16 μg/ml, 37.3% of isolates; ≥32 μg/ml, 7.9% of isolates), itraconazole (≥2 μg/ml, 1.0% of isolates), posaconazole (≥1 μg/ml, 1.0% of isolates), and voriconazole (≥2 μg/ml, 1.2% of isolates). However, mold-active triazoles exhibited low MICs for the majority of isolates tested. Additional correlation with patient outcomes to determine the relevance of elevated MICs in Coccidioides isolates is needed.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Coccidioides; amphotericin B; antifungal susceptibility testing; caspofungin; coccidioidomycosis; endemic mycoses; fluconazole; flucytosine; itraconazole; posaconazole; voriconazole

Mesh:

Substances:

Year:  2017        PMID: 28096163      PMCID: PMC5365710          DOI: 10.1128/AAC.02634-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model.

Authors:  G M González; R Tijerina; L K Najvar; R Bocanegra; M Luther; M G Rinaldi; J R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Call for a California coccidioidomycosis consortium to face the top ten challenges posed by a recalcitrant regional disease.

Authors:  George R Thompson; David A Stevens; Karl V Clemons; Josh Fierer; Royce H Johnson; Jane Sykes; George Rutherford; Michael Peterson; John W Taylor; Vishnu Chaturvedi
Journal:  Mycopathologia       Date:  2014-10-16       Impact factor: 2.574

3.  In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi.

Authors:  Gloria M González; Annette W Fothergill; Deanna A Sutton; Michael G Rinaldi; David Loebenberg
Journal:  Med Mycol       Date:  2005-05       Impact factor: 4.076

4.  Efficacies of two novel azole derivatives each containing a morpholine ring, UR-9746 and UR-9751, against systemic murine coccidioidomycosis.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

5.  Posaconazole therapy for chronic refractory coccidioidomycosis.

Authors:  David A Stevens; Adrian Rendon; Veronica Gaona-Flores; Antonino Catanzaro; Gregory M Anstead; Lisa Pedicone; J Richard Graybill
Journal:  Chest       Date:  2007-06-15       Impact factor: 9.410

6.  Persistent pulmonary infection with an azole-resistant Coccidioides species.

Authors:  John D Kriesel; Deanna A Sutton; Susan Schulman; Annette W Fothergill; Michael G Rinaldi
Journal:  Med Mycol       Date:  2008-09       Impact factor: 4.076

7.  Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America.

Authors:  Stanley W Chapman; William E Dismukes; Laurie A Proia; Robert W Bradsher; Peter G Pappas; Michael G Threlkeld; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2008-06-15       Impact factor: 9.079

8.  Treatment of pediatric refractory coccidioidomycosis with combination voriconazole and caspofungin: a retrospective case series.

Authors:  Emily R Levy; James M McCarty; Andi L Shane; Peggy S Weintrub
Journal:  Clin Infect Dis       Date:  2013-03-05       Impact factor: 9.079

9.  Therapeutic efficacy of caspofungin alone and in combination with amphotericin B deoxycholate for coccidioidomycosis in a mouse model.

Authors:  Gloria M González; Gerardo González; Laura K Najvar; John R Graybill
Journal:  J Antimicrob Chemother       Date:  2007-10-12       Impact factor: 5.790

10.  Evaluation of VT-1161 for Treatment of Coccidioidomycosis in Murine Infection Models.

Authors:  Lisa F Shubitz; Hien T Trinh; John N Galgiani; Maria L Lewis; Annette W Fothergill; Nathan P Wiederhold; Bridget M Barker; Eric R G Lewis; Adina L Doyle; William J Hoekstra; Robert J Schotzinger; Edward P Garvey
Journal:  Antimicrob Agents Chemother       Date:  2015-09-14       Impact factor: 5.191

View more
  17 in total

Review 1.  Early Events in Coccidioidomycosis.

Authors:  Fariba M Donovan; Lisa Shubitz; Daniel Powell; Marc Orbach; Jeffrey Frelinger; John N Galgiani
Journal:  Clin Microbiol Rev       Date:  2019-10-16       Impact factor: 26.132

2.  The Orotomide Olorofim Is Efficacious in an Experimental Model of Central Nervous System Coccidioidomycosis.

Authors:  Nathan P Wiederhold; Laura K Najvar; Rosie Jaramillo; Marcos Olivo; Michael Birch; Derek Law; John H Rex; Gabriel Catano; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

3.  The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis.

Authors:  Nathan P Wiederhold; Lisa F Shubitz; Laura K Najvar; Rosie Jaramillo; Marcos Olivo; Gabriel Catano; Hien T Trinh; Christopher M Yates; Robert J Schotzinger; Edward P Garvey; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

4.  Coccidioides immitis septic knee arthritis.

Authors:  Scott A Weisenberg
Journal:  BMJ Case Rep       Date:  2018-03-13

5.  Myelitis due to Coccidioidomycosis in an Immunocompetent Patient.

Authors:  Tetyana Vaysman; Sean Villaflores; Carlyn Estrella; Suman Radhakrishna; Antonio Liu
Journal:  Case Rep Infect Dis       Date:  2018-04-01

Review 6.  Central Nervous System Infections Due to Coccidioidomycosis.

Authors:  Niki R Jackson; Janis E Blair; Neil M Ampel
Journal:  J Fungi (Basel)       Date:  2019-06-28

7.  Coccidioidomycosis: Epidemiology, Fungal Pathogenesis, and Therapeutic Development.

Authors:  Hazael Hernandez; Victor H Erives; Luis R Martinez
Journal:  Curr Trop Med Rep       Date:  2019-06-14

8.  Infected Aneurysm of the Native Aorta due to Coccidioides posadasii.

Authors:  Jeffrey Huang; Edison J Cano; Fnu Shweta; Aditya S Shah; Audrey N Schuetz; Melanie Bois; Pooja R Gurram
Journal:  Open Forum Infect Dis       Date:  2021-05-23       Impact factor: 3.835

Review 9.  Review on Current Status of Echinocandins Use.

Authors:  Martyna Mroczyńska; Anna Brillowska-Dąbrowska
Journal:  Antibiotics (Basel)       Date:  2020-05-02

10.  APX001 and Other Gwt1 Inhibitor Prodrugs Are Effective in Experimental Coccidioides immitis Pneumonia.

Authors:  Suganya Viriyakosol; Mili Kapoor; Sharon Okamoto; Jonathan Covel; Quinlyn A Soltow; Michael Trzoss; Karen Joy Shaw; Joshua Fierer
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.